Conference Agenda
Monday, June 14
8:00 am Short Course and Early Conference Registration
PRE-CONFERENCE SHORT COURSE*
8:45 Hands-On Interactive Workshop:
Trust Building for Collaborative Innovation
Robert Porter-Lynch, Ph.D., CEO, The Warren Group; Managing Partner, System of Trust, LLC; Author, “Business Alliances: The Hidden Competitive Weapon”, and the forthcoming “Leadership & The Architecture of Trust”
Trust plays a massive role in the ability to generate innovation flows and underpins all cooperative enterprise including Collaborative Innovation. This “Trust Building for Collaborative Innovation” Workshop teaches you how to build a System of Trust, including Critical Concepts and Best Practices.
Topics to be covered include:
- Why people inadvertently create distrust
- The principle cause of distrust
- Why values and ethics often have no impact on trust
- How to balance self interest versus greater good
- Creating honorable purpose and acting with integrity
- Seven different types of trust relationships
- Seven typical trust busting behaviors
- Laws and principles of trust
- 12 actions to build/rebuild trust
- How to avoid the untrustworthy plus 20-point trust diagnostic
- Critical leadership issues to ensure trust underpins collaborative innovation
12:15 pm Close of Short Course
*Separate Registration Required
MAIN CONFERENCE PROGRAM
Introduction and Overview
1:30 Chair’s Opening Remarks
1:40 Building a System of Trust as the Foundation for Collaborative Innovation
Robert Porter-Lynch, Ph.D., CEO, The Warren Group; Managing Partner, System of Trust, LLC; Author, “Business Alliances: The Hidden Competitive Weapon”, and the forthcoming “Leadership & The Architecture of Trust”
Distrust is the Achilles Heel of collaborative innovation. Most people do things that inadvertently create distrust that undermines our creative energies. Learn the number one cause of distrust and the four most common traps that are sure to erode trust. How to determine what level of trust is appropriate for the working relationship; four key best practices sure to build trust; how to avoid those who are untrustworthy. Real world examples and case studies will be used to illustrate best practices in this field.
2:10 Can the Regulator and the Regulated Work Together to Advance Drug Safety Science? Rules and Process to Achieve Scientific Consensus, Impartial Review and the Adoption of Best Science in Safety Assessment
Eric Thompson, Ph.D., Assistant Director, Predictive Safety Testing Consortium, Critical Path Institute
Critical Path Institute, an independent non-profit entity formed in 2005 to support FDA’s Critical Path Initiative, facilitates several innovative consortia working to advance the drug development process and speed the delivery of safe, efficacious drugs to patients. C-Path’s Predictive Safety Testing Consortium (PSTC) is a collaboration of 16 major pharmaceutical companies sharing safety biomarker data, assay information, and samples to deliver convincing datasets to the FDA, EMA, and PMDA on novel safety biomarkers that can be utilized in regulatory decision-making. The PSTC has worked closely with these regulatory agencies to pilot and refine a biomarker qualification process that enables their early input as advisors but ensures impartial, objective regulatory review once a dataset is formally submitted. Several critical factors that contribute to the success and challenges of this pre-competitive, public-private partnership of industry and these regulatory bodies will be highlighted.
2:40 Is Open Innovation Right for Pharma?
Jackie Hunter, Ph.D., Senior Vice President, Science Environment Development, GlaxoSmithKline
A number of other industries have realized the benefits of an open innovation model of collaboration, which facilitates the management of internal intellectual property (IP) and its use to create value with external partners. Given that the pharmaceutical industry is now facing similar challenges to these industries, is there now a readiness to embrace an open innovation approach? The pharmaceutical industry has traditionally not been willing to devote the resources necessary to actively pursue an open innovation approach. In addition, the cultural changes required for such proactive IP management should not be underestimated. Examples of open innovation approaches from GSK, Lilly and other pharmaceutical companies will be discussed.
3:10 Networking Refreshment Break, Poster and Exhibit Viewing
3:45 The Long Tail in Collaborative Problem Solving: Experience with Internet-Facilitated Collaborative Innovation, Internally and with Vendors and Partners
Robin Spencer, Ph.D., Senior Fellow, Research Centers of Emphasis, Pfizer, Inc.
Chris Anderson’s “The Long Tail” highlights how the scale and economics of the internet, led by brands like Amazon and iTunes, have forever changed the landscape of retail. Similar analysis of very large data sets, from 3 years of managed innovation systems at Pfizer and elsewhere, show that many aspects of innovation (participation, ideation, idea triage, outcomes) also have robust long tail scale-free properties. We will show, by analysis and simulation, what the underlying human behaviors are that generate these observations, and thereby put innovation itself on a semiquantitative footing. Finally, we will explore the consequences of these root causes and robust observations as they apply to questions of scale, cost, infrastructure, expectations, and behavior.
4:15 A Publisher’s Perspective on the Challenges and Opportunities of Collaborative Innovation
Veronique Kiermer, Ph.D., Publisher, Nature Methods, Protocols, and Products, Nature Publishing Group
Nature Publishing Group is engaged in several initiatives that offer a window on some aspects of collaborative innovation. In particular, collaboration between industry and academic scientists, as individuals or organized groups, presents opportunities as well as challenges and cultural issues. Scientific publishers play an active role in promoting collaboration between scientists in the academic world. We will look at how this role extends to the pre-competitive environment of biomedical research.
4:45 Panel Discussion
5:15 Close of Day
For more details on the conference, please contact:
Phillips Kuhl
President
Cambridge Healthtech Institute
T: (+1) 781-972-5410
E: pkuhl@healthtech.com
For partnering and sponsorship information, please contact:
Arnie Wolfson
Manager, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431
E: awolfson@healthtech.com